Heidi J Gray1, Katherine Bell-McGuinn2, Gini F Fleming3, Mihaela Cristea4, Hao Xiong5, Danielle Sullivan6, Yan Luo7, Mark D McKee8, Wijith Munasinghe9, Lainie P Martin10. 1. University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: hgray@uw.edu. 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: katherinebellmcguinn@outlook.com. 3. The University of Chicago Medicine, Chicago, IL, USA. Electronic address: gfleming@medicine.bsd.uchicago.edu. 4. City of Hope National Medical Center, Duarte, CA, USA. Electronic address: MCristea@coh.org. 5. AbbVie Inc., North Chicago, IL, USA. Electronic address: Hao.Xiong@AbbVie.com. 6. AbbVie Inc., North Chicago, IL, USA. Electronic address: danielle.sullivan@abbvie.com. 7. AbbVie Inc., North Chicago, IL, USA. Electronic address: yan.luo@abbvie.com. 8. AbbVie Inc., North Chicago, IL, USA. Electronic address: mark.mckee@AbbVie.com. 9. AbbVie Inc., North Chicago, IL, USA. Electronic address: wijith.munasinghe@abbvie.com. 10. Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: lainie.martin@fccc.edu.
Abstract
OBJECTIVE: Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies. METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and ≤2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m2 on days 1 and 8 of a 21-day cycle for maximum 10cycles, followed by optional veliparib maintenance therapy. Veliparib dosing commenced twice-daily (BID) continuously on day 1 of cycle 2; granulocyte colony-stimulating factor was permitted. Dose escalation used a Bayesian continual reassessment method. Safety, tolerability, and efficacy were evaluated. RESULTS: Seventy-five patients were enrolled (ovarian cancer, n=54; breast cancer, n=12). Thirty-six patients with ovarian cancer (67%) had known germline BRCA mutations. Most common treatment-related adverse events (TRAEs; ≥60%) were thrombocytopenia, neutropenia, nausea, and anemia. Most common grade 3/4 TRAEs (≥40%) were neutropenia and thrombocytopenia. Dose-limiting toxicities were thrombocytopenia and neutropenia. The MTD/RP2D was established at veliparib 250mg with carboplatin AUC 4 plus gemcitabine 800mg/m2. Responses were observed in 69% of patients with BRCA-deficient ovarian cancer (45% partial, 24% complete responses). Five patients remained on veliparib (80-310mg BID) for >34cycles. CONCLUSIONS: Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations. Trial registration ID: NCT01063816.
OBJECTIVE: Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies. METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and ≤2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m2 on days 1 and 8 of a 21-day cycle for maximum 10cycles, followed by optional veliparib maintenance therapy. Veliparib dosing commenced twice-daily (BID) continuously on day 1 of cycle 2; granulocyte colony-stimulating factor was permitted. Dose escalation used a Bayesian continual reassessment method. Safety, tolerability, and efficacy were evaluated. RESULTS: Seventy-five patients were enrolled (ovarian cancer, n=54; breast cancer, n=12). Thirty-six patients with ovarian cancer (67%) had known germline BRCA mutations. Most common treatment-related adverse events (TRAEs; ≥60%) were thrombocytopenia, neutropenia, nausea, and anemia. Most common grade 3/4 TRAEs (≥40%) were neutropenia and thrombocytopenia. Dose-limiting toxicities were thrombocytopenia and neutropenia. The MTD/RP2D was established at veliparib 250mg with carboplatin AUC 4 plus gemcitabine 800mg/m2. Responses were observed in 69% of patients with BRCA-deficient ovarian cancer (45% partial, 24% complete responses). Five patients remained on veliparib (80-310mg BID) for >34cycles. CONCLUSIONS:Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancerpatients with germline BRCA mutations. Trial registration ID: NCT01063816.
Authors: Kathleen N Moore; Austin Miller; Katherine M Bell-McGuinn; Russell J Schilder; Joan L Walker; Roisin E O'Cearbhaill; Saketh R Guntupalli; Deborah K Armstrong; Andrea R Hagemann; Heidi J Gray; Linda R Duska; Cara A Mathews; Alice Chen; David O'Malley; Sarah Gordon; Paula M Fracasso; Carol Aghajanian Journal: Gynecol Oncol Date: 2019-11-07 Impact factor: 5.482
Authors: Junior Gonzales; Susanne Kossatz; Sheryl Roberts; Giacomo Pirovano; Christian Brand; Carlos Pérez-Medina; Patrick Donabedian; M Jason de la Cruz; Willem J M Mulder; Thomas Reiner Journal: Bioconjug Chem Date: 2018-11-07 Impact factor: 4.774
Authors: Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: M Mego; D Svetlovska; M Reckova; K Kalavska; J Obertova; P Palacka; K Rejlekova; Z Sycova-Mila; M Chovanec; J Mardiak Journal: Invest New Drugs Date: 2021-05-29 Impact factor: 3.850